Logomix, Inc., a Tokyo-based mammalian synthetic biology company developing artificial human cells for new therapeutics based on its pioneering Geno-Writing™ platform technology, announced that it has successfully raised $3.9 million USD in seed funding. The company’s oversubscribed financing was led by Angel Bridge with participation from JAFCO, Tokyo IPC, Sand Hill Angels, Yasunori Kaneko (former Managing Director at Skyline Ventures), and more.
The company intends to use the funds to continue building out the Geno-Writing™ platform, further validate the technology through partnerships with biotech and pharma, and to establish automation capabilities of cell engineering and operations in the United States, where Logomix seeks senior and junior scientists in the field.
Geno-Writing™ is Logomix’s innovative genome engineering platform to write large-scale and complex messages into a genome. It will enable therapy developers to write therapeutics sequences to develop new modalities and cure serious diseases such as cancer, neurodegenerative diseases, and genetic diseases under discovery collaborations with biopharma companies.
By pioneering a completely novel genome writing platform approach, Logomix can help the Cell and Gene Therapy (CGT) industry accelerate the delivery of the transformative therapies to patients in need.
Angel Bridge, a venture capital that invests and provides hands-on support mainly to seed- to earlystage companies, joined Logomix’s seed funding round. “The synthetic biology market is an area that is attracting worldwide attention, with many world-class startups emerging mainly in the U.S. Logomix's core technology is novel and attractive in that it can edit the genome extensively, rather than editing it at a point. What is also distinctive about Logomix is Taiki, Yasunori, and their team’s rare sense of balance, combined with their knowledge of the industry and their advanced technical capabilities in the field of synthetic biology. We firmly believe that Logomix has the potential to become a world-class startup, and Angel Bridge will do its utmost to support Logomix to realize its full potential.” said Mr.Yutaro Kasai at Angel Bridge.
Sand Hill Angels, is a group of successful Silicon Valley centered entrepreneurs and executives who are passionate about identifying and supporting next generation disruptive technology, joined Logomix’s seed funding round. “We view Logomix as being at the forefront of solving many of the significant challenges now facing CGT researchers and developers. Their innovative technology approach has the potential to be both enabling and game changing” said Jeff Depew, President of Sand Hill Angels. “We are delighted to support Taiki, Yas and their team in their endeavor and believe, with their complimentary skills, leadership and technology, Logomix represents the future of the field.”
Logomix is a Tokyo-based synthetic biology company, enabling large-scale and complex genome modifications in human cells than ever. Logomix is currently creating various versions of artificial human cells by its proprietary genome engineering platform Geno-Writing™ to drive revolution in Pharmaceutical industry for drug discovery, cell therapy, and anti-aging. For more information, visit https://logomix.bio/en.
About Angel Bridge
Angel Bridge is a venture capital that invests and provides hands-on support mainly to seed- to earlystage companies. We invest in startups that have the potential to become world-class startups that will revolutionize the world in the future. We stand out by building a team with prior experiences in top-tier professional firms. We provide hands-on support to help entrepreneurs achieve full potential by leveraging our extensive experiences in contributing to the growth of many companies.
About Sand Hill Angels
Sand Hill Angels (SHA) is a Global group of angel investors centered in Silicon Valley, passionate about helping entrepreneurs get to the next level. What makes the group unique is the mentoring, collective network and experience of its members building and scaling deep technology companies from inception to exit. For over two decades Sand Hill Angels has worked openly and collaboratively with venture capital funds, other angel organizations, and the Bay Area ecosystem that fosters the growth of technology startups in Enterprise, Life Science and Consumer markets. SHA typically invests in Seed, Series A and follow-on rounds.